CartiHeal

Company Overview

Snapshot

Founded in June 2009 by Nir Altschuler, CartiHeal operates with 11–50 employees. The company raised a total of $74 million across 7 funding rounds from 8 investors. In November 2023, CartiHeal was acquired by Smith & Nephew.

Business overview

CartiHeal develops proprietary implants for treating cartilage and osteochondral defects in traumatic and osteoarthritic joints. Its core product, Agili-C, is a cell-free, off-the-shelf, rigid, biphasic, and biodegradable implant. The implant's bone phase uses calcium carbonate in aragonite crystalline form, while the cartilage phase combines modified aragonite and hyaluronic acid. CartiHeal serves the orthopedic and regenerative medicine markets, focusing on medical devices and medical treatment & therapeutics within the Health Tech & Life Sciences sector.

Strategic signal

In November 2023, CartiHeal was acquired by Smith & Nephew. This acquisition signals a significant validation of CartiHeal's Agili-C implant technology and its potential to address cartilage and osteochondral defects, reinforcing the strategic value of innovative regenerative medicine solutions in the medical device industry.

Company Intelligence Q&A

What is CartiHeal's primary product?

CartiHeal's primary product is Agili-C, a cell-free, off-the-shelf implant designed for the treatment of cartilage and osteochondral defects.

When was CartiHeal acquired?

CartiHeal was acquired by Smith & Nephew in November 2023.

Did CartiHeal receive FDA approval for its implant?

Yes, the FDA approved CartiHeal's implant for the treatment of cartilage and osteochondral defects in March 2022.

When did CartiHeal receive FDA Breakthrough Device Designation for Agili-C?

CartiHeal received FDA "Breakthrough Device Designation" for its Agili-C implant in October 2020.

When did CartiHeal announce the first commercial implantation of Agili-C in the US?

CartiHeal announced the first commercial implantation of Agili-C in the US in July 2023.